A
Agnieszka Jagiełło-Gruszfeld
Researcher at Curie Institute
Publications - 57
Citations - 7933
Agnieszka Jagiełło-Gruszfeld is an academic researcher from Curie Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 16, co-authored 44 publications receiving 7394 citations.
Papers
More filters
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Journal ArticleDOI
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier,Anna Pluzanska,Piotr Koralewski,Alain Ravaud,Sergio Bracarda,Cezary Szczylik,Christine Chevreau,Marek Filipek,Bohuslav Melichar,Emilio Bajetta,Vera Gorbunova,Jacques-Olivier Bay,Istvan Bodrogi,Agnieszka Jagiełło-Gruszfeld,Nicola Moore +14 more
TL;DR: In this article, the authors investigated the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa, and reported a significant improvement in progression-free survival.
Journal ArticleDOI
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron,Michelle Casey,Michael F. Press,Deborah Lindquist,Tadeusz Pienkowski,C. Gilles Romieu,Stephen Chan,Agnieszka Jagiełło-Gruszfeld,Bella Kaufman,John Crown,Arlene Chan,Mario Campone,Patrice Viens,Neville Davidson,Veira Gorbounova,Johannes Isaac Raats,Dimosthenis Skarlos,B. Newstat,Debasish F. Roychowdhury,Paolo Paoletti,Cristina Oliva,Stephen D. Rubin,S. Stein,Charles E. Geyer +23 more
TL;DR: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.
Journal ArticleDOI
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt,Christine Theodore,Tomasz Demkov,Boris Komyakov,Lisa Sengeløv,Gedske Daugaard,Armelle Caty,Joan Carles,Agnieszka Jagiełło-Gruszfeld,Oleg Karyakin,François-Michel Delgado,Patrick Hurteloup,Eric Winquist,N. Morsli,Yacine Salhi,Stéphane Culine,Hans von der Maase +16 more
TL;DR: Overall response rate, disease control, and progression-free survival were all statistically significant favoring VFL + BSC, and therefore, VFL seems to be a reasonable option for TCCU progressing after first-line platinum-based therapy.
Journal ArticleDOI
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga,Seock–Ah –A Im,Hiroji Iwata,Javier Cortes,Michele De Laurentiis,Zefei Jiang,Carlos L. Arteaga,Walter Jonat,Mark Clemons,Yoshinori Ito,Ahmad Awada,Stephen Chia,Agnieszka Jagiełło-Gruszfeld,Barbara Pistilli,Ling Ming Tseng,Sara A. Hurvitz,Norikazu Masuda,Masato Takahashi,Peter Vuylsteke,Soulef Hachemi,Bharani Dharan,Emmanuelle di Tomaso,Patrick Urban,Cristian Massacesi,Mario Campone +24 more
TL;DR: This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in patients with advanced breast cancer, including an evaluation of the PI3K pathway activation status as a biomarker for clinical benefit.